Skip to main content
main-content

01.12.2014 | Original Article | Ausgabe 6/2014 Open Access

Virchows Archiv 6/2014

SATB1 is an independent prognostic factor in radically resected upper gastrointestinal tract adenocarcinoma

Zeitschrift:
Virchows Archiv > Ausgabe 6/2014
Autoren:
Charlotta Hedner, Alexander Gaber, Dejan Korkocic, Björn Nodin, Mathias Uhlén, Eugenia Kuteeva, Henrik Johannesson, Karin Jirström, Jakob Eberhard
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s00428-014-1667-6) contains supplementary material, which is available to authorized users.

Abstract

Gastric cancer is the second most common cause of cancer-related death worldwide, and the incidence of esophageal adenocarcinoma is rising. While some progress has been made in treatment strategies, overall survival remains very poor for patients with adenocarcinoma in the upper gastrointestinal tract. Special AT-rich sequence binding protein 1 (SATB1) is a global genome organizer that has been demonstrated to promote aggressive tumor behavior in several different types of cancer, including gastric cancer. The prognostic value of SATB1 expression in esophageal cancer has, however, not yet been described. In this study, expression of SATB1 was examined by immunohistochemistry on tissue microarrays prepared from tissue samples from 175 patients with adenocarcinoma of the esophagus, cardia, or stomach and containing normal tissue, intestinal metaplasia, primary tumors, and metastases. A well-validated antibody was used. We found SATB1 to be an independent prognostic factor in patients with a radically resected tumor, correlating with shorter overall survival as well as with shorter recurrence-free survival. SATB1 expression was also found to be significantly lower in primary tumors associated with intestinal metaplasia than those without intestinal metaplasia. This observation is of potential biological interest as it has been proposed that intestinal metaplasia-associated tumors constitute a less aggressive phenotype.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Zusatzmaterial
ESM 1 (DOCX 95 kb)
428_2014_1667_MOESM1_ESM.docx
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 6/2014

Virchows Archiv 6/2014 Zur Ausgabe

Neu im Fachgebiet Pathologie

27.11.2018 | Hauptreferate: Tumorevolution II | Sonderheft 2/2018

Zirkulierende Tumorzellen beim Pankreaskarzinom

Ergebnisse morphologischer und molekularer Analysen und Vergleiche mit dem Primärtumor

23.11.2018 | Hauptreferate: Hauptprogramm der DGP | Sonderheft 2/2018

Das Urachuskarzinom – aktuelle Konzepte einer seltenen Tumorerkrankung

16.11.2018 | Hauptreferate: Hauptprogramm der DGP | Sonderheft 2/2018

Das Deutsche Mesotheliomregister

Aktuelle pathologische Diagnostik und Leistungen

14.11.2018 | Originalien | Ausgabe 6/2018

Retinale Blutungen beim Schütteltrauma

Differenzialdiagnostische Aspekte